The 411 on a GLP-1

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/c2/33/d1/c233d1db-34f1-b8c4-5f4f-62796e35ded9/mza_7311540209202604384.jpg/600x600bb.jpg

The 411 on a GLP-1

Novo Nordisk

3 episodes

3 weeks ago

Join series hosts Dr. Jim Gavin, Clinical Professor of Medicine at Emory University and Chief Medical Officer at Healing Our Village, in Atlanta, GA; Dr. Jennifer Goldman, Professor of Pharmacy at Massachusetts College of Pharmacy, in Boston, MA, and Clinical Pharmacist at Well Life Medical, in Peabody, MA, and other fellow leaders in the field of diabetes as they tackle some of the challenges we face when treating T2D. Topics of discussion include the disease state of T2D, the role of GLP-1 in glucose regulation, guidelines on early use of GLP-1 RAs in T2D treatment, as well as the mechanism of action, dosing and administration, efficacy and safety profiles, handling and storage, and education of patients and pharmacists for a once-daily GLP-1 RA for adults with T2D. This podcast series is sponsored by Novo Nordisk and is intended for clinicians.

All content for The 411 on a GLP-1 is the property of Novo Nordisk and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Education,

Health & Fitness

Episodes (3/3)

The 411 on a GLP-1

Patient-Focused Care in T2D: The Pharmacist’s Role in GLP-1 RA Education

What is the role of the pharmacist in patient-centered care of adults with type 2 diabetes (T2D)? Join pharmacist experts in T2D Jennifer Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, Melody Hartzler, PharmD, BCACP, BC-ADM, AE-C, and Donald Nuzum, PharmD, BCACP, BC-ADM, CDCES, as they discuss education of patients and pharmacists on the pharmacokinetics, administration, dosing schedule, and handling of a GLP-1 receptor agonist (GLP-1 RA). They will also consider when to use a GLP-1 RA, as they review clinical data on efficacy and safety of a GLP-1 RA, including in a trial when used as monotherapy vs placebo, a head-to-head study vs a DPP-4 inhibitor, and a cardiovascular outcomes study.

1 month ago

48 minutes 16 seconds

The 411 on a GLP-1

How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RA

Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.

1 month ago

35 minutes 20 seconds

The 411 on a GLP-1

Could This GLP-1 RA be Right for Your Adult Patients With T2D?

Join leaders in the field of diabetes, Dr. Jim Gavin, Dr. Pablo Mora, and Dr. Bob Busch, as they navigate through a clinical study. What do you need to know about using a GLP-1 RA for glycemic control with patients who have T2D? Are there any considerations for specific populations such as those who have moderate renal impairment?

1 month ago

25 minutes 15 seconds